Simvastatin Alleviates Pathology in a Rat Model of Preeclampsia Involving the ERK/MAPK Pathway

This is a laboratory animal study probing whether statins might help in preeclampsia, and by what biological mechanism.

In a rat model of the disorder, simvastatin lowered blood pressure, restored the balance of pro- and anti-angiogenic factors, reduced inflammation and oxidative stress, and activated the ERK/MAPK signaling pathway in the placenta. The authors propose this pathway as the route of benefit, suggesting therapeutic potential.

The findings are preclinical and mechanistic. Rat models of preeclampsia translate imperfectly to human pregnancy, and — tellingly — the well-designed human trial of pravastatin for preeclampsia (Döbert 2021) found no clinical benefit. This study illustrates a plausible mechanism that did not, in the end, pan out in patients.

We rate the evidence limited. As animal work it is far from clinical application, and it is best read alongside the negative human trial as a cautionary example of why mechanism in a rodent does not guarantee benefit in people.